Delivering Therapies: Overcoming Barriers
For years, delivering to the Central Nervous System (CNS) and taking therapies across the Blood-Brain Barrier (BBB) has impeded the efforts to find realistic and safe therapies for the CNS diseases. We have built SMDG's research and development platform on the guiding principles that a safe and effective delivery platform will allow scientists to create better and efficacious medicines for many neurological diseases and that an effective broad delivery platform should work for many other diseases too. With that in mind, we set out to design our platform in order to create better medicines and more effective and safe therapies.
NanoCarrier Ligands (NLC) are a new novel class of nanoparticles. NLCs are unique self-assembled peptidic particulate systems that target the blood-brain barrier as well as other biological barriers.
SMDG's innovative and patent-protected NLC technology could be used for targeted delivery of therapeutic and diagnostic agents.
The NLC technology is based on "safe-by-design" and "simple-by-design" concepts that actively deliver therapeutic molecules to the target cells.
NanoLigand Carriers (NLC)
Drug delivery to the brain: self-assembled phage mimetics for crossing the blood-brain-barrier
We show that hierarchical forms of a phage display peptide efficiently target the brain and ferry nucleic acid medicines to neurons and microglia